Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RedHill Biopharma ( (RDHL) ) has provided an announcement.
On October 17, 2025, RedHill Biopharma announced a strategic partnership with Cumberland Pharmaceuticals, involving a $4 million investment for a 30% stake in Talicia Holdings, a subsidiary managing the global rights to Talicia®. This partnership includes a five-year co-commercialization agreement in the U.S., with both companies sharing net revenues and operational responsibilities. The collaboration aims to boost Talicia’s market presence and financial performance, reinforcing RedHill’s financial position and compliance with Nasdaq listing requirements.
The most recent analyst rating on (RDHL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
RedHill Biopharma’s overall stock score is primarily impacted by its challenging financial performance, characterized by consistent losses and high leverage. The technical analysis indicates weak momentum, and the lack of valuation metrics further underscores financial instability. These factors collectively suggest a high-risk investment profile.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology, primarily in the U.S. Its key product, Talicia®, is an FDA-approved treatment for Helicobacter pylori infection in adults.
Average Trading Volume: 1,394,971
Technical Sentiment Signal: Sell
Current Market Cap: $4.99M
Find detailed analytics on RDHL stock on TipRanks’ Stock Analysis page.